Home › NCT06232876

Continuous Versus Intermittent Ward Monitoring

Continuous Versus Intermittent Ward Monitoring on Vital Sign Abnormalities, Clinical Interventions, and Serious Complications: the CONSTANT Trial

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Are admitted to one of the wards equipped with the Masimo Radius PPG and Rad-97 monitors;
2. Are ≥18 years old;
3. Are designated American Society of Anesthesiologists physical status 1-4;
4. Had major noncardiac surgery lasting at least 1.5 hours;
5. Are expected to remain hospitalized at least two postoperative nights;
6. Had general anesthesia with or without neuraxial anesthesia.

Exclusion Criteria:

1. Have language, vision, or hearing impairments that may compromise continuous monitoring;
2. Are designated Do Not Resuscitate, hospice, or receiving end of life care;
3. Have previously participated in the study.

About the study

The investigators will randomize adults having major non-cardiac inpatient surgery to blinded versus unblinded continuous postoperative vital sign monitoring (saturation, ventilation, and heart rate). The investigators will use a wearable, untethered, and battery-powered sensor (Masimo Radius PPG, Masimo, Irvine, CA) that wirelessly connects to a Masimo monitor and continuously records saturation, ventilation, and pulse rate.

The primary outcome will be areas-exceeding-thresholds for desaturation (\<85%), bradypnea (\<7 breaths/min), tachypnea (\>30 breaths/min), tachycardia (heart rate \>130 beats/min), and bradycardia (heart rate \<45 beats/min). These exposure thresholds represent a balance between events that are clinically meaningful and excessive alarms that will discourage clinician participation. The investigators expect about 1 alert per patient per day with these thresholds, with most being considered informative or actionable by nurses. In unblinded patients, clinician alerts will be activated at these thresholds.

What is being tested

• Blinded continuous vital sign monitoring (device)
• Unblinded continuous vital sign monitoring (device)

Sponsor: The University of Texas Health Science Center, Houston · Participants: 492 · Started: Aug 17, 2026

Contact the study team

• Muhammad Omar Naeem, MD · Phone: (713) 500-4383
• Daniel Sessler, MD · Phone: 713-500-3062

Official record on ClinicalTrials.gov — NCT06232876

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.